← Back to patent-cliff list
Henagliflozin/metformin/retagliptin (Shandong Shengdi)
Tier C — Watch / tradeHenagliflozin/metformin/retagliptin (Shandong Shengdi)
-
Originator
2025
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：DPP4, SGLT2, PRKAB1
Indications (approved)：Type 2 diabetes, Diabetes
Regional status
US
-
EU
-
China
Approved
2025-10-21
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Henagliflozin/metformin/retagliptin (Shandong Shengdi)?
Approved indications include: Type 2 diabetes, Diabetes.
When does the Henagliflozin/metformin/retagliptin (Shandong Shengdi) patent expire?
No public expiry year is available for Henagliflozin/metformin/retagliptin (Shandong Shengdi) yet; this page updates once verified.
How do I get a quote for Henagliflozin/metformin/retagliptin (Shandong Shengdi) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01